Zhou, J., Sturtevant, D., Love, C., Kulkarni, A., Biyani, N., Kathad, U., … Bhatia, K. (2023). Addendum: LP-284, a small molecule acylfulvene, exerts potent antitumor activity in preclinical non-Hodgkin's lymphoma models and in cells deficient in DNA damage repair. Oncotarget, 14, 722. https://doi.org/10.18632/oncotarget.28479

Zhou, Jianli, Drew Sturtevant, Cassie Love, Aditya Kulkarni, Neha Biyani, Umesh Kathad, Elizabeth Thacker, Sandeep Dave, and Kishor Bhatia. “Addendum: LP-284, a small molecule acylfulvene, exerts potent antitumor activity in preclinical non-Hodgkin's lymphoma models and in cells deficient in DNA damage repair.” Oncotarget 14 (July 20, 2023): 722. https://doi.org/10.18632/oncotarget.28479.

Zhou J, Sturtevant D, Love C, Kulkarni A, Biyani N, Kathad U, et al. Addendum: LP-284, a small molecule acylfulvene, exerts potent antitumor activity in preclinical non-Hodgkin's lymphoma models and in cells deficient in DNA damage repair. Oncotarget. 2023 Jul 20;14:722.

Zhou, Jianli, et al. “Addendum: LP-284, a small molecule acylfulvene, exerts potent antitumor activity in preclinical non-Hodgkin's lymphoma models and in cells deficient in DNA damage repair.” Oncotarget, vol. 14, July 2023, p. 722. Pubmed, doi:10.18632/oncotarget.28479.

Zhou J, Sturtevant D, Love C, Kulkarni A, Biyani N, Kathad U, Thacker E, Dave S, Bhatia K. Addendum: LP-284, a small molecule acylfulvene, exerts potent antitumor activity in preclinical non-Hodgkin's lymphoma models and in cells deficient in DNA damage repair. Oncotarget. 2023 Jul 20;14:722.